Industry Press Releases

Chugai's Hemlibra receives approval from the European Commission for severe haemophilia A without factor VIII inhibitors

Saturday, Mar 16, 2019

Chugai Pharmaceutical Co today announced that Roche has received a decision from the European Commission confirming that Hemlibra® (emicizumab), a haemophilia A treatment from Chugai, has been authorized in the EU for routine adult prophylaxis of bleeding children with severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors. The EU Commission has also approved that Hemlibra can be used with multiple dosing options (once a week, every two weeks or every four weeks) for all designated persons with haemophilia A, including those with factor VIII inhibitors.

This announcement is officially valid in the original source language. Translations are only meant as reading aids and must be compared with the text in the source language, which is the only one valid.

Contacts
For Media

Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp

For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com

For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu

For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw

For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

 

Source: businesswire.com

Other Press Releases